Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0WEEMU)
| ADC Name |
AT-03
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
AT-03; AT-03 (Axcynsis); AT03-65;AT65474
Click to Show/Hide
|
|||||
| Organization |
Axcynsis Therapeutics (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Anti-CLDN6 antibody
|
Antibody Info | ||||
| Antigen Name |
Claudin-6 (CLDN6)
|
Antigen Info | ||||
| Payload Name |
TCS132 (AxcynDOT)
|
Payload Info | ||||
| Payload Target |
Human deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Oesophageal cancer | ||||
| Gastroesophageal junction adenocarcinoma | ||||
| Gastric cancer | ||||
| Lung cancer | ||||
| Peritoneal cancer | ||||
| Breast cancer | ||||
| Ovarian cancer | ||||
| Fallopian tube cancer | ||||
| Endometrial cancer | ||||
| Unspecific solid tumor |